| Literature DB >> 8112239 |
L L Radulovic1, B J Wilder, I E Leppik, H N Bockbrader, T Chang, E L Posvar, A J Sedman, B M Uthman, G R Erdman.
Abstract
Gabapentin (GBP) studies were conducted in patients with epilepsy receiving carbamazepine (CBZ, n = 12) or valproate (VPA, n = 14) monotherapy. The effects of GBP coadministration on steady-state CBZ or VPA concentrations and of these antiepileptic drugs (AEDs) on GBP pharmacokinetics were investigated. GBP (400 mg) was coadministered every 8 h for 3 1/3 days with CBZ or for 5 1/3 days with VPA. GBP was well tolerated. Mean steady-state plasma CBZ/CBZ-10,11-epoxide (CBZ-E) and serum VPA concentrations before, during, and after GBP administration were not significantly different. Mean steady-state GBP pharmacokinetic parameters during CBZ or VPA coadministration were similar to steady-state parameters reported in healthy subjects. Thus, no pharmacokinetic interaction exists between CBZ or VPA and GBP. No dosage adjustment is necessary when GBP and CBZ or VPA are coadministered.Entities:
Mesh：
Substances：
Year: 1994 PMID： 8112239 DOI： 10.1111/j.1528-1157.1994.tb02926.x
Source DB: PubMed Journal: Epilepsia ISSN： 0013-9580 Impact factor: 5.864